AngioSafe

AngioSafe is a private, clinical-stage medical device company pioneering a new approach to endovascular revascularization for peripheral artery disease (PAD), specifically targeting chronic total occlusions (CTOs). Its core innovation is the Atheroplasty™ platform, which combines intraplaque cutting, compression, and channel formation in a single, wire-free device, aiming to simplify complex procedures and reduce complications like embolism and dissection. The company's technology is supported by positive data from the RESTOR-1 pivotal trial, positioning it to address a significant unmet need in the large and growing peripheral vascular market.

Atheroplasty™ - a wire-free, single-step endovascular platform combining intraplaque cutting, compression, and channel formation for crossing and preparing chronic total occlusions (CTOs).

AngioSafe competes in the peripheral vascular crossing and atherectomy device market, dominated by large players like Boston Scientific, Medtronic, Philips, and Abbott. Its primary competition includes specialty guidewires, re-entry devices, and orbital/rotational atherectomy systems. AngioSafe's key differentiation is its wire-free, all-in-one approach designed to reduce procedure steps and complications.